HomeCompareWPDPF vs MRK

WPDPF vs MRK: Dividend Comparison 2026

WPDPF yields 6666666.67% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WPDPF wins by $8.25873857526507e+44M in total portfolio value
10 years
WPDPF
WPDPF
● Live price
6666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.25873857526507e+44M
Annual income
$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00
Full WPDPF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — WPDPF vs MRK

📍 WPDPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWPDPFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WPDPF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WPDPF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WPDPF
Annual income on $10K today (after 15% tax)
$566,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$701,972,065,618,006,100,000,000,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, WPDPF beats the other by $701,972,065,618,006,100,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WPDPF + MRK for your $10,000?

WPDPF: 50%MRK: 50%
100% MRK50/50100% WPDPF
Portfolio after 10yr
$4.129369287632535e+44M
Annual income
$412,924,744,481,180,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

WPDPF
No analyst data
Altman Z
-107.3
Piotroski
0/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WPDPF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWPDPFMRK
Forward yield6666666.67%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$8.25873857526507e+44M$57.7K
Annual income after 10y$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00$10,113.78
Total dividends collected$8.258722632802889e+44M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: WPDPF vs MRK ($10,000, DRIP)

YearWPDPF PortfolioWPDPF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$666,677,367$666,666,666.67$11,213$373.04+$666.67MWPDPF
2$41,538,243,978,220$41,537,530,633,437.17$12,667$512.06+$41538243.97MWPDPF
3$2,418,785,178,923,619,000$2,418,740,733,002,562,000.00$14,439$708.14+$2418785178923.60MWPDPF
4$131,632,535,180,835,430,000,000$131,629,947,080,693,970,000,000.00$16,640$988.16+$131632535180835424.00MWPDPF
5$6,694,929,569,421,761,000,000,000,000$6,694,788,722,609,116,000,000,000,000.00$19,432$1,394.07+$6.69492956942176e+21MWPDPF
6$318,233,313,948,923,370,000,000,000,000,000$318,226,150,374,284,100,000,000,000,000,000.00$23,057$1,992.90+$3.1823331394892335e+26MWPDPF
7$14,137,160,116,927,522,000,000,000,000,000,000,000$14,136,819,607,281,600,000,000,000,000,000,000,000.00$27,889$2,894.79+$1.4137160116927522e+31MWPDPF
8$586,942,647,681,175,100,000,000,000,000,000,000,000,000$586,927,520,919,850,000,000,000,000,000,000,000,000,000.00$34,518$4,286.29+$5.8694264768117504e+35MWPDPF
9$22,774,359,015,829,920,000,000,000,000,000,000,000,000,000,000$22,773,730,987,196,898,000,000,000,000,000,000,000,000,000,000.00$43,912$6,494.35+$2.277435901582992e+40MWPDPF
10$825,873,857,526,507,000,000,000,000,000,000,000,000,000,000,000,000$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00$57,714$10,113.78+$8.25873857526507e+44MWPDPF

WPDPF vs MRK: Complete Analysis 2026

WPDPFStock

WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat central nervous system tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of glioblastoma multiforme that is in the pre-clinical trial; and Annamycin to treat acute myeloid leukemia (AML) and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Full WPDPF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this WPDPF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WPDPF vs SCHDWPDPF vs JEPIWPDPF vs OWPDPF vs KOWPDPF vs MAINWPDPF vs JNJWPDPF vs ABBVWPDPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.